相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Joachim Albers et al.
MOLECULAR CANCER THERAPEUTICS (2023)
Cancer statistics, 2023
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
Automated next-generation profiling of genomic alterations in human cancers
Laurel A. Keefer et al.
NATURE COMMUNICATIONS (2022)
Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors
James P. Solomon et al.
CLINICAL CANCER RESEARCH (2022)
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy
Anna Kron et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Crizotinib in Patients With MET-Amplified NSCLC
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
MET Amplification in Non-Small Cell Lung Cancer (NSCLC)-A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting
Christoph Schubart et al.
CANCERS (2021)
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
Lun-Xi Peng et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).
Xiuning Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study
Sergey V. Orlov et al.
TRANSLATIONAL ONCOLOGY (2021)
Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer
Chen Lin et al.
FRONTIERS IN ONCOLOGY (2020)
The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
Shaokun Liu et al.
FRONTIERS IN ONCOLOGY (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Michael Offin et al.
CLINICAL CANCER RESEARCH (2019)
Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns
Sergi Clave et al.
CLINICAL LUNG CANCER (2019)
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
Yudong Su et al.
TARGETED ONCOLOGY (2019)
Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non-Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases
Anna Scattone et al.
TRANSLATIONAL ONCOLOGY (2019)
Update on emerging biomarkers in lung cancer
Eric H. Bernicker et al.
JOURNAL OF THORACIC DISEASE (2019)
Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer
Chen Lin et al.
LUNG CANCER (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neat I. Lindeman et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A machine learning approach for somatic mutation discovery
Derrick E. Wood et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance
Claudia Vollbrecht et al.
BMC CANCER (2018)
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
Ryosuke Okamura et al.
JCO PRECISION ONCOLOGY (2018)
ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?
Florian Cabillic et al.
ESMO OPEN (2018)
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians
Michael Allgaeuer et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Next-Generation Assessment of Human Growth Factor Receptor 2 (ERBB2) Amplification Status Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay
Dara S. Ross et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations
Rafael Caparica et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
Ravi Salgia
MOLECULAR CANCER THERAPEUTICS (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy
Jeffrey S. Ross et al.
ONCOLOGIST (2017)
Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS
Xiaomin Niu et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Immunohistochemistry for predictive biomarkers in non-small cell lung cancer
Mari Mino-Kenudson
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer
Tatsuya Yoshida et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
Sinead A. Noonan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations
Yan Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Yoon Jin Cha et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
ROS1 copy number alterations are frequent in non-small cell lung cancer
Sergi Clave et al.
ONCOTARGET (2016)
Efficacy of crizotinib in ALK fusion variants
Tetsu Kobayashi et al.
JOURNAL OF THORACIC DISEASE (2016)
Identification of a Novel Fusion Gene, IRF2BP2-RARA, in Acute Promyelocytic Leukemia
C. Cameron Yin et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
ALK FISH and IHC You Cannot Have One without the Other
Yasushi Yatabe
JOURNAL OF THORACIC ONCOLOGY (2015)
Next-Generation Sequencing and Immunohistochemistry as Future Gold Standard of ALK Testing in Lung Cancer?
Arnaud Uguen et al.
ONCOLOGIST (2015)
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
David Casadevall et al.
ONCOTARGET (2015)
MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung
Hans-Ulrich Schildhaus et al.
CLINICAL CANCER RESEARCH (2015)
Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients
Joana Vidal et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
Puey Ling Chia et al.
CLINICAL EPIDEMIOLOGY (2014)
Targeting MET Amplification as a New Oncogenic Driver
Hisato Kawakami et al.
CANCERS (2014)
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
Rafal Dziadziuszko et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
Heounjeong Go et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
分享论文
